Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

285 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Use of angiogenesis inhibitors in tumour treatment.
Fayette J, Soria JC, Armand JP. Fayette J, et al. Among authors: armand jp. Eur J Cancer. 2005 May;41(8):1109-16. doi: 10.1016/j.ejca.2005.02.017. Eur J Cancer. 2005. PMID: 15911233 Review.
[PI3K-AKT-mTOR pathway inhibitors].
Cortot A, Armand JP, Soria JC. Cortot A, et al. Among authors: armand jp. Bull Cancer. 2006 Jan;93(1):19-26. Bull Cancer. 2006. PMID: 16455502 Free article. Review. French.
Phase I-IIa study of BMS-690514, an EGFR, HER-2 and -4 and VEGFR-1 to -3 oral tyrosine kinase inhibitor, in patients with advanced or metastatic solid tumours.
Soria JC, Baselga J, Hanna N, Laurie SA, Bahleda R, Felip E, Calvo E, Armand JP, Shepherd FA, Harbison CT, Berman D, Park JS, Zhang S, Vakkalagadda B, Kurland JF, Pathak AK, Herbst RS. Soria JC, et al. Among authors: armand jp. Eur J Cancer. 2013 May;49(8):1815-24. doi: 10.1016/j.ejca.2013.02.012. Epub 2013 Mar 13. Eur J Cancer. 2013. PMID: 23490650 Clinical Trial.
Human epidermal receptor family inhibitors in patients with ERBB3 mutated cancers: Entering the back door.
Verlingue L, Hollebecque A, Lacroix L, Postel-Vinay S, Varga A, El Dakdouki Y, Baldini C, Balheda R, Gazzah A, Michot JM, Marabelle A, Mir O, Arnedos M, Rouleau E, Solary E, De Baere T, Angevin E, Armand JP, Michiels S, André F, Deutsch E, Scoazec JY, Soria JC, Massard C. Verlingue L, et al. Among authors: armand jp. Eur J Cancer. 2018 Mar;92:1-10. doi: 10.1016/j.ejca.2017.12.020. Epub 2018 Feb 3. Eur J Cancer. 2018. PMID: 29413684
Radiological patterns of tumour progression in patients treated with a combination of immune checkpoint blockers and antiangiogenic drugs.
Guiard E, Baldini C, Pobel C, Assi T, Bernard-Tessier A, Martin-Romano P, Hollebecque A, Verlingue L, Geraud A, Michot JM, Armand JP, Soria JC, Massard C, Ammari S. Guiard E, et al. Among authors: armand jp. Eur J Cancer. 2022 May;167:42-53. doi: 10.1016/j.ejca.2022.02.024. Epub 2022 Apr 1. Eur J Cancer. 2022. PMID: 35378410
Cutaneous side-effects of kinase inhibitors and blocking antibodies.
Robert C, Soria JC, Spatz A, Le Cesne A, Malka D, Pautier P, Wechsler J, Lhomme C, Escudier B, Boige V, Armand JP, Le Chevalier T. Robert C, et al. Among authors: armand jp. Lancet Oncol. 2005 Jul;6(7):491-500. doi: 10.1016/S1470-2045(05)70243-6. Lancet Oncol. 2005. PMID: 15992698 Review.
285 results